MET amplification is not rare and predicts unfavorable clinical outcomes in patients with recurrent/metastatic gastric cancer after chemotherapy

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|120|5|675-682

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.5, 2014-03, pp. : 675-682

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Expression of orphan nuclear receptor NR4A2 in gastric cancer cells confers chemoresistance and predicts an unfavorable postoperative survival of gastric cancer patients with chemotherapy

By  

CANCER, Vol. 119, Iss. 19, 2013-10 ,pp. : 3436-3445

John Wiley & Sons Inc

Access to resources Recommend Favorite

Influence of Socioeconomic Status on Survival and Clinical Outcomes in Patients with Advanced Gastric Cancer after Chemotherapy

By  

Oncology Research and Treatment, Vol. 37, Iss. 6, 2014-05 ,pp. : 310-314

Karger

Access to resources Recommend Favorite

Genetic Polymorphisms of FcγRIIa and FcγRIIIa Are Not Predictive of Clinical Outcomes after Cetuximab plus Irinotecan Chemotherapy in Patients with Metastatic Colorectal Cancer

By  

Oncology, Vol. 82, Iss. 2, 2012-02 ,pp. : 83-89

Karger

Access to resources Recommend Favorite

BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer

By  

CANCER, Vol. 120, Iss. 15, 2014-08 ,pp. : 2316-2324

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long-Term Clinical Remission in a Patient with Metastatic Gastric Cancer after Palliative Chemotherapy

By  

Oncology Research and Treatment, Vol. 23, Iss. 5, 2000-11 ,pp. : 464-466

Karger

Access to resources Recommend Favorite